Alle Storys
Keine Story von BB Biotech AG mehr verpassen.

BB Biotech AG

DGAP-News: BB BIOTECH AG: Annual report 2016

DGAP-News: BB BIOTECH AG / Key word(s): Final Results
BB BIOTECH AG: Annual report 2016 (news with additional features)

17.02.2017 / 07:00
The issuer is solely responsible for the content of this announcement.

Media release as of February 17, 2017

Annual report of BB Biotech AG as of December 31, 2016

BB Biotech AG publishes its 2016 annual report

BB Biotech AG published its annual report for fiscal 2016 today. Besides the
audited consolidated financial statements, the annual report contains detailed
information on the biotechnology sector, BB Biotech's positioning, the
therapeutic areas covered by its portfolio and the companies it is invested in.

As disclosed in the report, BB Biotech ended the year with a slightly positive
total return of 0.3% in CHF and 1.9% in EUR despite the considerable
difficulties the past year posed for biotech investors. Its Net Asset Value
(NAV) declined by 19.1% in CHF, 17.6% in EUR and 20.6% in USD, which was
somewhat better than the benchmark Nasdaq Biotech Index. The performance of BB
Biotech's shares in 2016 largely reflects the dissolution of the discount to
NAV. The consolidated and audited accounts show a net loss of CHF 802 mn for
fiscal 2016 compared to a net profit of CHF 653 mn in the previous year.

As already announced on January 20, 2017, BB Biotech will propose an ordinary
dividend of CHF 2.75 per share at the upcoming Annual General Meeting, which
represents a yield of 5% based on the volume-weighted average price of BB
Biotech shares in December 2016. This marks a continuation of the dividend
policy as introduced in 2013.

BB Biotech's annual report 2016 can be downloaded

For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel.
+41 44 267 67 00
Dr. Silvia Schanz,
Maria-Grazia Iten-Alderuccio,
Claude Mikkelsen,

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel.
+41 44 267 67 00
Tanja Chicherio,

b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland, Tel. +41 79 423 22
Thomas Egger,

Company profile
BB BIOTECH invests in companies in the fast-growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.

This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the current
expectations of BB Biotech, its directors and officers, and are, therefore,
subject to risks and uncertainties that may change over time. As actual
developments may significantly differ, BB Biotech and its directors and officers
accept no responsibility in that regard. All forward-looking statements included
in this release are made only as of the date of this release and BB Biotech and
its directors and officers assume no obligation to update any forward-looking
statements as a result of new information, future events or other factors.
Additional features:

Document title: Media release

17.02.2017  Dissemination of a Corporate News, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at

Language: English


          Schwertstrasse 6

          8200 Schaffhausen


Phone:    +41 52 624 08 45

Fax:      +41 1 267 67 01



ISIN:     CH0038389992

WKN:      A0NFN3

Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX


End of News DGAP News Service


545123  17.02.2017 

Weitere Storys: BB Biotech AG
Weitere Storys: BB Biotech AG